Search filters

Filters
Clear All

Phase

  • 1
  • 8
  • 1
  • 2
  • 15
  • 9
  • 15

Found 15 Heart Disease trials

A listing of Heart Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 DCPMS: Dialated Cardiomyopathy Precision Medicine Study
1 years - 100 years
All genders
This study aims to understand the effects of potential familial/genetic links in an otherwise unclear origin of a patient's heart disease.
 Electrogram Guided Myocardial Advanced Phenotyping (EMAP) Study for patients recently diagnosed with cardiomyopathy
18 years - 100 years
All genders
Phase 3
This study is enrolling newly diagnosed heart failure (within 6 months from diagnosis) patients with no known cause for their heart disease. We are utilizing already used technology, voltage mapping capabilities used in electrophysiology procedures, to more directly target weaker areas of the left and right ventricles. our physicians would …
 LIFE  Study: Entresto TM in Advanced Heart Failure
18 years - 100 years
All genders
Phase 3
This study aims to understand the benefits/risks of Entresto in NYHA III-IV patients.
18 years - 100 years
All genders
We are looking for healthy volunteers to donate bone marrow for research purposes. The Stem Cell & Xenograft Core provides bone marrow to laboratories on Penn’s campus researching leukemia and other blood disorders
 AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke
99 years or below
All genders
Phase 3
Reliance Agreement Request
 Multicenter open-label study to evaluate efficacy of gadobutrolenhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or suspected CAD by a blinded image analysis
1 years - 99 years
All genders
Phase 3
The primary efficacy objectives of this study are to demonstrate that sensitivity and specificity of gadobutrol-enhanced CMRI exceed prespecified minimum performance thresholds (MPT) of 60% and 55%, respectively and to show superior sensitivity over unenhanced wall motion CMRI at vasodilator rest/stress for the detection of significant coronary artery disease (CAD) …
 Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.
18 years - 99 years
All genders
Phase 3
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD. Five hundred and fifty-two (552) evaluable subjects will be enrolled in this study, and will undergo SPECT MPI and Flurpiridaz (18F) Injection PET MPI, …
 Cardiovascular Inflammation Reduction Trial (CIRT):  A randomized  double-blind  placebo controlled  event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome
1 years - 99 years
All genders
Phase 4
This is an event-driven, multi-center, randomized, double-blind, placebo-controlled trial to determine whether methotrexate reduces heart attacks, strokes, or death in people who have already had at least one heart attack and have type 2 diabetes or metabolic syndrome. Metabolic syndrome is defined as a combination of problems including a large …
 (PREDICT) A Multi-Center Study in Patients Undergoing Anthracycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment
1 years - 99 years
All genders
Over the past 2 decades, there has been a significant increase in life span of patients with cancer so that now, there are more than 10 million cancer survivors in the U.S. [1]. There is a growing recognition that although survival has improved, many long-term side effects including cardiac complications …
 Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors
99 years or below
All genders
Phase 2
Since 2006, there has been a 50% increase in the number of adults added to the heart transplant waitlist in the US. Yet the persistent organ donor shortage has led to only a 25% increase in the number of transplants, and a 25% increase in the number of patients removed …
1 - 10 of 15